Abstract |
This paper presents a review of the literature on the therapeutic action and the side effects of the two main dopaminergic agents: L-DOPA/ decarboxylase inhibitor ( L-DOPA/DI) and bromocriptine ( Parlodel used either as monotherapy or in combination in patients with Parkinson's disease. The combination of L-DOPA/DI and bromocriptine gives the best therapeutic efficacy (49% improvement) in the total score ( bradykinesia, rigidity and tremor). However, treatment by monotherapy or combination gives the same pattern of activity: greatest improvement in tremor, followed by rigidity and bradykinesia. Improvement observed in the short term is not sustained over longer periods of time for monotherapy with either drug. The short-term side effects are similar for each treatment, whereas long-term complications ( dyskinesia, end-of-dose deterioration and on-off phenomenon) appear only when levodopa is used, alone (high incidence) or in combination with bromocriptine (low incidence). The overall optimum treatment is obtained with a combination of L-DOPA/DI and bromocriptine.
|
Authors | S Bouchard |
Journal | The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
(Can J Neurol Sci)
Vol. 14
Issue 3 Suppl
Pg. 460-5
(Aug 1987)
ISSN: 0317-1671 [Print] England |
PMID | 3676921
(Publication Type: Journal Article)
|
Chemical References |
- Drug Combinations
- Bromocriptine
- Levodopa
|
Topics |
- Aged
- Bromocriptine
(administration & dosage, adverse effects, therapeutic use)
- Drug Combinations
- Humans
- Levodopa
(administration & dosage, adverse effects, therapeutic use)
- Middle Aged
- Movement Disorders
(etiology)
- Parkinson Disease
(complications, drug therapy)
- Time Factors
|